Therefore, further investigation to determine the best treatment strategy for the simultaneous or continuous use of EGFR-TKIs or MEK inhibitors and ICIs in EGFR-mutant NSCLC is needed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.